Insider trade

Officer sold ~$112K of ALKS shares in the open market

Traded Jan 2, 2026 · Filed Jan 2, 2026

Why it stands out

Alkermes's R&D, Chief Medical Officer sold $112K of Alkermes shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Officer$100K–$500KPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$112,000

Shares × reported transaction price

Timing vs results

66 days after results of Oct 28, 2025, 10 days before results of Jan 12, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	+5.8%	+1.1%	+4.7%
30 days	+21.9%	−0.2%	+22.1%
90 days	+21.7%	−4.2%	+25.9%
180 days	+96.9%	+9.2%	+87.7%

Past results only. Not a forecast.

This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.

9mo ago

Derivative exercise or conversion — not an open-market buy.

Scheduled in advance9mo ago

9mo ago

Derivative exercise or conversion — not an open-market buy.